1307741-29-2

Upstream product

• 25245-33-4 1-iodo-2,3-dimethoxybenzene 
• 109-73-9 N-butylamine 
• 91-16-7 1,2-dimethoxybenzene 

Downstream Products

• 1307741-44-1 N-butyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,3-dimethoxyphenyl]-2-iodobenzamide 
• 1307741-47-4 C₂₃H₂₄F₆INO₅ 
• 1307741-50-9 N-butyl-N-[4-(2-benzyloxy-1,1,1,3,3,3-hexafluoropropan-2-yl)-2,3-dimethoxyphenyl]-2-iodobenzamide 
• 1307741-54-3 C₃₀H₃₀F₆INO₅ 
• 1307741-58-7 2-(2-benzyloxy-1,1,1,3,3,3-hexafluoropropan-2-yl)-5-butyl-3,4-dimethoxyphenanthridin-6(5H)-one 
• 1307741-62-3 2-(2-benzyloxy-1,1,1,3,3,3-hexafluoropropan-2-yl)-5-butyl-3,4,8-trimethoxyphenanthridin-6(5H)-one 
• 1307741-30-5 2-(4-butylamino-2,3-dimethoxyphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 

Relevant academic research and scientific papers

THERAPEUTIC AGENT FOR HEPATITIS C

This invention provides a therapeutic agent for hepatitis C comprising, as an active ingredient, a compound having anti-HCV activity useful in treatment of hepatitis C. The therapeutic agent for hepatitis C comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Fused heterocyclic amido compounds as anti-hepatitis C virus agents

We identified a fused heteroaromatic amido structure based on the phenanthridine skeleton as a superior scaffold for candidate drugs with potent anti-HCV activity. Among the compounds synthesized, a phenanthridine analogue with a 1,3-dioxolyl group (24) possessed the most potent anti-HCV activity (EC50 value: 50 nM), with acceptable cytotoxicity. The structural development and structure-activity relationships of these compounds are described.